S-227928

N/A

Report date: 2025/10/15 20:01:42

Base Information

Drug NameS-227928
Drug Alias NameS-227928S227928
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VK linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > S64315 payload
Mechanisms of ActionAnti-CD74Induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors
TargetsHLA-DR antigens-associated invariant chainInduced myeloid leukemia cell differentiation protein Mcl-1
Therapy Area/IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLeukemia, Myelomonocytic, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaGermany +[6] 
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLes Laboratoires Servier
China Registration ClassN/A

Develop Information

Active CompaniesVernalis PlcLes Laboratoires Servier
Inactive CompaniesServier Bio-Innovation LLC
Active IndicationsHematologic Neoplasms
Inactive IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A